BCOP Updates 2025: Hope for a GENEration: Recent Advancements in Sickle Cell Disease
Breakthroughs in the treatment of Sickle Cell Disease (SCD) had been sparse since the U.S. Food and Drug Administration approved hydroxyurea to treat the disease in the late 1990s. However, in the last seven years there have been a number of advancements made in the management of this debilitating genetic disease. The approval of two new gene therapies in particular has revolutionized the treatment of SCD and offers hope for a cure. While this session will include a review of other recent approvals (L-glutamine, voxelotor, and crizanlizumab), the discussion will focus on the use of gene therapy for the treatment of SCD.
BCOP Updates 2025: Hope for a GENEration: Advancements in Sickle Cell Disease
Authors: Mary Catherine Cash, PharmD, BCOP, and Elizabeth Rogers Eubanks, PharmD, MPH, BCPS, BCOP, CPP
Learning Objectives
- Describe the pathophysiology of Sickle Cell Disease (SCD) and its associated complications
- Analyze primary literature surrounding the efficacy and safety of L-glutamine, voxelotor, and crizanlizumab
- Summarize primary literature surrounding the use of exagamglogene autotemcel and lovotibeglogene autotemcel for the treatment of SCD
- Design an appropriate supportive care regimen for a patient receiving gene therapy for SCD
- Compare available treatment options for SCD
Get it now!
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.